The debate highlighted that G2019S shows elevated baseline RAB10 phosphorylation, but it's unclear whether this represents true signal amplification during lysosomal swelling or just a higher activity floor. This distinction is crucial for understanding disease mechanisms and therapeutic targeting.
Source: Debate session sess_SDA-2026-04-16-gap-pubmed-20260410-170027-a1e5f867_20260416-135352 (Analysis: SDA-2026-04-16-gap-pubmed-20260410-170027-a1e5f867)
The most supported model is that pathogenic G2019S shifts the basal catalytic set-point upward, producing higher baseline phospho-Rab output while leaving the core lysosomal volume-sensing response architecture largely intact. In this view, mutant cells begin from a higher activity floor, and the key experimental discriminator is whether baseline-normalized EC50, slope, or Emax materially increase during graded swelling.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["LRRK2 Primary Target"]
B["Biological Process 1 Mechanistic Step A"]
C["Biological Process 2 Mechanistic Step B"]
D["Output Phenotype Disease Effect"]
A --> B
B --> C
C --> D
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style D fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
9 citations9 with PMID5 mediumValidation: 0%7 supporting / 2 opposing
✓For(7)
5
No opposing evidence
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
5
2
2
MECH 5CLIN 2GENE 2EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Mitochondrial ROS promotes susceptibility to infec…
Endogenous G2019S shows only modest phospho-Rab elevation compared with stronger ROC-COR mutants, consistent w…▼
Endogenous G2019S shows only modest phospho-Rab elevation compared with stronger ROC-COR mutants, consistent with a modest catalytic bias rather than a major gain increase.
Membrane recruitment is sufficient to trigger Rab phosphorylation, implying recruitment may be the main activa…▼
Membrane recruitment is sufficient to trigger Rab phosphorylation, implying recruitment may be the main activation event and G2019S may add a higher baseline set-point onto that pathway.
Elevated phospho-Rab biomarkers in carriers could also reflect altered membrane dwell time, substrate access, …▼
Elevated phospho-Rab biomarkers in carriers could also reflect altered membrane dwell time, substrate access, or phosphatase balance rather than a simple baseline-only effect.
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-24 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Title: `G2019S raises the LRRK2 kinase floor more than the swelling gain`
Mechanism: G2019S may primarily increase constitutive catalytic output, producing higher baseline pRab10/pRab12 without materially changing the slope of the lysosomal volume-response curve. In this model, swelling still activates the same upstream lysosomal recruitment/activation circuit, but mutant cells start from a higher baseline rather than showing stronger fold-amplification.
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Skeptical Read
The main weakness across all six is the same: most cited evidence shows that mutant `LRRK2` can elevate phospho-Rab output or alter lysosomal remodeling, but it does not cleanly separate `baseline offset` from `stimulus gain`. Much of the literature uses overexpression, artificial membrane targeting, `LLOME` or lysosomotropic stress, PBMCs, or macrophage-like cells. Those systems are useful for mechanism discovery, but they are not decisive for the specific question “does G2019S amplify volume sensing, or just raise the floor?”
**`G2019S raises the kinase floor more
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
As of April 24, 2026, the hypotheses that most credibly survive are:
#1 Higher baseline kinase activity more than higher swelling gain
#4 Amplification is context-dependent and strongest in microglia/macrophages
#5 `pRab12` may be the better translational biomarker under chronic lysosomal stress
#6 A downstream `LRRK2-Rab10/JIP4` lysosomal stress to α-syn release loop is plausible
#2 LYTL/JIP4 remodeling is a useful mechanistic phenotype, but not yet a primary therapeutic thesis
#3 phosphatase buffering survives as an assay-interpretation modifier,
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{ "ranked_hypotheses": [ { "title": "G2019S primarily raises baseline LRRK2 kinase activity rather than amplifying lysosomal swelling gain", "description": "The most supported model is that pathogenic G2019S shifts the basal catalytic set-point upward, producing higher baseline phospho-Rab output while leaving the core lysosomal volume-sensing response architecture largely intact. In this view, mutant cells begin from a higher activity floor, and the key experimental discriminator is whether baseline-normalized EC50, slope, or Emax materially increase during graded swelling."
IF primary fibroblasts or iPSC-derived neurons carrying G2019S LRRK2 are compared to isogenic wild-type controls, THEN phospho-Rab10 (Ser106) or phospho-Rab8A (Ser72) levels will be significantly elevated at baseline (no lysosomal stress) by at least 30-50% as measured by quantitative immunoblot or targeted proteomics, WITHIN 3 months.
pendingconf: 0.75
Expected outcome: Baseline phospho-Rab10/Rab8A levels will be higher in G2019S carriers than in isogenic controls
Falsified by: No significant difference in baseline phospho-Rab10/Rab8A levels between G2019S and WT cells (t-test p > 0.05 or fold-change < 1.3)
Method: Primary dermal fibroblasts from G2019S carriers (n≥6 per genotype) or iPSC-derived cortical/mesencephalic neurons with isogenic G2019S/WT pairs; quantitative immunoblot for phospho-Rab10 (Ser106) or phospho-Rab8A (Ser72) normalized to total Rab; ELISA or targeted MRM as alternative quantification.
IF G2019S and WT cells are treated with graded concentrations of osmotic lysosomal stressors (mannitol, sucrose, or nigericin) for 2-24 hours, THEN the baseline-normalized dose-response curve for phospho-Rab10 will show no material increase in EC50, Emax, or Hill slope in G2019S versus WT, WITHIN 6 months.
pendingconf: 0.65
Expected outcome: Normalized EC50, Emax, and Hill slope for phospho-Rab10 induction will be comparable between G2019S and WT (difference < 20%)
Falsified by: G2019S cells show >20% increase in baseline-normalized Emax or >2-fold leftward shift in EC50, or significantly steeper Hill slope, indicating true amplification of the swelling response rather than mere baseline elevation
Method: iPSC-derived dopaminergic neurons or patient fibroblasts treated with increasing doses of osmotic stressors (mannitol: 50-300 mM; nigericin: 1-10 μM); phospho-Rab10/Rab8A measured by quantitative immunoblot at each dose; baseline values subtracted to generate normalized curves; non-linear regression for EC50/Emax/Hill slope; n≥4 biological replicates per condition.